Sopharma AD (WSE:SPH)

Poland · Delayed Price · Currency is PLN

7.60

-0.08 (-1.04%)

Aug 14, 2026, 4:08 PM CET

-40.39% (1Y)

Market Cap	4.41B +63.4%
Revenue (ttm)	6.00B +20.1%
Net Income	346.39M +81.5%
EPS	0.99 +172.9%
Shares Out	n/a
PE Ratio	12.74
Forward PE	n/a
Dividend	0.41 (5.45%)
Ex-Dividend Date	Jul 9, 2026

Volume	39
Open	7.60
Previous Close	7.68
Day's Range	7.60 - 7.60
52-Week Range	6.04 - 11.65
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Medical Distribution

Sector Healthcare

Founded 1933

Employees 6,005

Stock Exchange Warsaw Stock Exchange

Ticker Symbol SPH

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial numbers in EUR Financial Statements